3Netea MG, van der Meer JW, van Deuren M, et al. Proinflammatory cytokines and sepsis syndrome:not enough, or too much of a good thing? Trends Immunol, 2003, 24: 254-258.
4Knotzesr H, Pajk W, Dunser MW, et al. Regional microvascular function and vascular reactivity in patients with different degrees of multiple organ dysfunction syndrome. Anesth Analg, 2006, 102 : 1187-1193.
5Wago M, Shimooka T. Extracorporeal blood purification (renal replacement therapy). Nihon Rinsho, 2011, 69: 534-540.
6Silvester W. Mediator removal with CRRT: complement and cytokines. Am J Kidney Dis, 1997, 30: 38-43.
7Peng Y, Yuan Z, Li H. Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis. Burns, 2005, 31 : 623-628.
8Fehervari I, Fazakas J, Gerlei Z, et al. Mitigation of cytokine storm by intraoperative use of renal replacement therapy during combined liver-kidney transplantation. Transplant Proc, 2010, 42 : 2353-2356.
9Garcia-Fernandez N, Lavilla FJ, Rocha E, et al. Haemostatic changes in systemic inflammatory response syndrome during continuous renal replacement therapy. J Nephrol, 2000, 13: 282- 289.
10Reinharc K, Menges T, Gardlund B, et al. Randomized, placebo-contreled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyper inflammatory response during severe sepsis: The RAMSES Study. Cri Care Med, 2001,29: 765-769.
